We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia.
- Authors
Karousi, Paraskevi; Katsaraki, Katerina; Papageorgiou, Sotirios G.; Pappa, Vasiliki; Scorilas, Andreas; Kontos, Christos K.
- Abstract
Chronic lymphocytic leukemia (CLL) is a type of leukemia during which CD5+ B lymphocytes accumulate in marrow and lymphoid tissues.[1] CLL patients are mostly adults, usually elderly people,[2] and their clinical features vary considerably.[3] The clinical phase of the patients is determined by two staging systems, Binet or Rai, portraying three and five noteworthy prognostic groups, respectively.[[4]] The clinical stage of the disease, the mutational status of the immunoglobulin heavy chain variable ( I IGHV i ) region, and loss or mutation of the I TP53 i gene are considered as the most valid prognostic markers in CLL.[[6]] Some auxiliary factors are also taken into consideration for their prognostic value. In light of this cutoff, we grouped the CLL patients in two particular subgroups, namely, i-tRF-GlyGCC-positive and i-tRF-GlyGCC-negative patients. The estimated median OS was 73 months (95% CI, 44-102 mo). i-tRF-GlyGCC-positive CLL patients have shorter OS time intervals, compared with i-tRF-GlyGCC-negative CLL patients, as revealed by Kaplan-Meier analysis ( I P i = .001; Figure). Although i-tRF-GlyGCC expression cannot be used to distinguish between CLL patients and nonleukemic blood donors, since the levels of this tRF in both cohorts' PBMCs are not significantly different, we examined further the prognostic value of this RNA fragment in CLL.
- Subjects
CHRONIC lymphocytic leukemia; RNA; RNA interference; CHRONIC leukemia
- Publication
Hematological Oncology, 2019, Vol 37, Issue 4, p498
- ISSN
0278-0232
- Publication type
letter
- DOI
10.1002/hon.2616